Peer-reviewed veterinary case report
Intrathecal Newcastle disease vaccine tested for dogs with distemper
By Harkin, Kenneth R & Karote, Anushka George·Published in Journal of the American Animal Hospital Association·2022·From the Department of Clinical Sciences (K.R.H.)·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of Intrathecal Injection of Modified Live Newcastle Disease Virus Vaccine in Dogs with Canine Distemper Encephalitis.
- Species:
- dog
Plain-English summary
Thirteen dogs with canine distemper virus (CDV) infection and neurological symptoms were treated with an injection of a modified live Newcastle disease virus vaccine to see if it could help. Unfortunately, while six of the dogs survived to be re-evaluated after a few months, only four lived longer than three years. The treatment did not show a clear benefit in improving their condition or survival rates. As a result, this vaccine injection is not recommended for treating dogs with neurological issues caused by CDV.
People also search for: dog distemper treatment · canine distemper symptoms · Newcastle disease vaccine for dogs · dog neurological problems treatment
Abstract
The neurological form of canine distemper virus (CDV) infection can occur concurrently with systemic signs or develop following apparent recovery. There are no specific antiviral or immunomodulatory therapies recognized for treatment of CDV infections, and the neurological form typically carries with it a high mortality rate. The intrathecal injection of a modified live Newcastle disease virus vaccine (NDV-MLV) has been proposed for the treatment of the neurological forms of CDV infections. Thirteen dogs confirmed to have canine distemper infections by polymerase chain reaction testing and with neurological signs consistent with CDV infection were treated with an intrathecal injection of NDV-MLV and were scheduled for re-evaluation 3-4 mo later. Six dogs survived to follow-up and four dogs survived long term (>3 yr). Cerebrospinal fluid cytokines were measured and reported. Changes in cerebrospinal fluid cytokines and long-term survival could not be attributed to the intrathecal injection of NDV-MLV, and this therapy cannot be recommended for treatment of dogs with neurological forms of CDV infection.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35576400/